Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p144 | (1) | ICCBH2019

A multi-criteria decision analysis of the value of burosumab for the treatment of paediatric patients with X-linked hypophosphatemia in Portugal

Alves Ines , Francisco Telma , Pinto Helena , Sousa Sergio , Connor Paul , Amorim Miguel , Ramos Diogo , Azevedo Sofia , Vandewalle Bjorn

Objectives: Burosumab is an anti-FGF23 fully human monoclonal antibody, recently approved for the treatment of X-linked hypophosphatemia (XLH), presenting a novel treatment approach compared to conventional therapy (CT), composed of oral phosphate and active vitamin D. The objective of this study is to perform a Multi-Criteria Decision Analysis (MCDA) to assess the value of burosumab for the treatment of paediatric patients with XLH in Portugal, in comparison to CT.<p clas...

ba0001pp136 | Cancer and bone: basic, translational and clinical | ECTS2013

Modulation of macrophage activation status by bisphosphonates and breast cancer cells

Sousa Sofia , Monkkonen Jukka , Maatta Jorma

Tumour stromal macrophages differentiate into tumour associated macrophages (TAMs), with characteristics resembling the immunosuppressive M2 polarization instead of the pro-inflammatory M1. TAMs have a central role in promoting tumour vascularization, cancer cell dissemination and suppression of anti-cancer immune response. Cancer cell dissemination leads to metastasis formation which, e.g. in breast cancer often happens in bone marrow. We have studied the in vitro mo...

ba0001pp368 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Portuguese and spanish FRAX® tool versions: a comparative analysis from EpiReumaPt

Gouveia Nelia , Canhao Helena , Rego Tania , Sousa Susana , Branco Jaime

EpiReumaPt is a cross-sectional, epidemiologic study to estimate the prevalence of rheumatic diseases in Portugal. Selected cases randomized from the 10 000 Portuguese subjects recruited are eventually observed by a rheumatologist. Portuguese and Spanish FRAX® tool were applied. The major osteoporotic (MOFR) and hip (HFR) fracture risk were calculated without DXA results.The FRAX tool has been developed by WHO to evaluate 10 years fracture risk. It ...

ba0001pp81 | Bone development/growth and fracture repair | ECTS2013

Characterization of an Y1R antagonist as a drug for bone regeneration

Alencastre Ines , Almeida Catarina , Leite Diana , Alves Cecilia , Sousa Daniela , Neto Estrela , Lamghari Meriem

Recently, Y1 receptor (Y1R) has arisen as a potential regulator in the local control of bone turnover. BIBP3226 is a potent Y1R selective antagonist that was successfully used in in vitro studies showing a positive impact in the benefit of bone turnover, thus providing good perspectives for its use as a pharmacological tool for bone regeneration.However, BIBP3226 behaviour in a complex milieu such as the bone compartment is unknown. As drugs can...

ba0003oc1.6 | Phosphate metabolism, fracture repair and osteoarthritis | ECTS2014

The role of neuropeptide Y Y1 receptor signalling in fracture healing

Sousa Daniela M , McDonald Michelle M , Mikulec Kathy , Peacock Lauren , Little David G , Herzog Herbert , Lamghari Meriem , Baldock Paul A

Recent studies have demonstrated that the global or osteoblast-specific deletion of neuropeptide Y Y1 receptor (Y1R), as well as the pharmacological blockade of Y1R, leads to pronounced anabolic effects in bone metabolism. This suggests that anti-Y1R drug therapy might have clinical applications for the prevention/recovery of bone loss occurring in osteoporosis. Given the high fracture incidence in this target population, it remained...

ba0001pp324 | Osteoporosis: evaluation and imaging | ECTS2013

Strong diagnostic agreement between a novel ultrasound-based method for lumbar densitometry and dual-energy X-ray absorptiometry

Muratore Maurizio , Conversano Francesco , Casciaro Ernesto , Soloperto Giulia , Franchini Roberto , Greco Antonio , Quarta Eugenio , Casciaro Sergio

Introduction: Currently, osteoporosis is mainly diagnosed through dual-enargy X-ray absorptiometry (DXA). However, DXA cannot be used for early diagnoses through population mass screenings because of issues related to ionizing radiation employment. Aim of this study is to perform a preliminary clinical validation of a new ultrasound (US)-based method for vertebral densitometry.Methods: A total of 270 women were included in this study according to the fol...

ba0003pp13 | Arthritis and other joint diseases: translational and clinical | ECTS2014

RANK expression is reduced in circulating monocytes from ankylosing spondylitis patients

Perpetuo Ines Pedro , Caetano-Lopes Joana , Vieira-Sousa Elsa , Campanilho-Marques Raquel , Ponte Cristina , Canhao Helena , Ainola Mari , Fonseca Joao Eurico

Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are systemic, immune-mediated diseases. RA’s main targets are the peripheral joints while AS has the axial skeleton and enthesis as the principal affected areas. RA is characterized by bone erosions and impaired repair whilst AS is typified by bone overgrowth. The causes for these differences are not yet understood; however we hypothesize that AS patients’ monocytes receive reduced osteoclastogenic stimuli and...

ba0005cabs.oc1.1 | Oral Communications | ECTS2016

Secreted YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases

Bettencourt Maria , Ferreira Arlindo , Alho Irina , Lucia Costa Ana , Sousa Ana Rita , Mansinho Andre , Abreu Catarina , Pulido Catarina , Macedo Daniela , Vendrell Ines , Pacheco Teresa , Costa Luis , Casimiro Sandra

YB-1 (Y-box binding protein 1) is a multifunctional cold-shock protein that has been implicated in all hallmarks of cancer. Elevated YB-1 protein levels were correlated with poor prognosis in several types of cancers, including breast cancer (BC). In BC, high YB-1 expression is a marker of decreased overall survival (OS) and distant metastasis-free survival across all subtypes. YB-1 is also secreted by different cell types and may act as an extracellular mitogen. Therefore, ou...

ba0005p194 | Cell biology: osteoclasts and bone resorption | ECTS2016

Neuropetide Y Y1 receptor deletion impairs matrix demineralization and resorption

Sousa Daniela M , Conceicao Francisco , Leitao Luis , Neto Estrela , Alves Cecilia J , Alencastre Ines S , Herzog Herbert , Aguiar Paulo , Lamghari Meriem

Neuropeptide Y Y1 receptor (Y1R) signalling has been shown to play a key role in bone homeostasis, emerging as a novel therapeutic target in bone diseases. Y1R knockout mice (Y1−/−) display a high-bone mass phenotype that has been mainly attributed to increased osteoblast activity. Nevertheless, the Y1R regulatory role on osteoclastogenesis and matrix resorption remains largely unknown. To clarify th...